PRME:NSD-Prime Medicine, Inc. Common Stock (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 3.15

Change

-0.13 (-3.96)%

Market Cap

N/A

Volume

0.50M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+3.79 (+0.93%)

USD 104.84B
REGN Regeneron Pharmaceuticals Inc

+3.29 (+0.45%)

USD 78.92B
ARGX argenx NV ADR

+0.64 (+0.10%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

+4.60 (+1.95%)

USD 30.22B
MRNA Moderna Inc

-4.36 (-9.17%)

USD 18.29B
UTHR United Therapeutics Corporatio..

+4.28 (+1.18%)

USD 15.91B
RPRX Royalty Pharma Plc

+0.16 (+0.61%)

USD 15.05B
SMMT Summit Therapeutics PLC

+0.66 (+3.63%)

USD 13.43B
INCY Incyte Corporation

-0.06 (-0.08%)

USD 13.41B
BMRN Biomarin Pharmaceutical Inc

+0.48 (+0.71%)

USD 12.74B

ETFs Containing PRME

XDNA 5.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.88% 73% C 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.88% 73% C 84% B
Trailing 12 Months  
Capital Gain -63.71% 26% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.71% 26% F 11% F
Trailing 5 Years  
Capital Gain -84.43% 40% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -84.43% 40% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain -23.63% 17% F 10% F
Dividend Return -23.63% 17% F 10% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.01% 92% A 68% D+
Risk Adjusted Return -90.85% 9% A- 5% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector